Target intelligence / Profile preview

Egyptian cobra venom toxins (NhV) (NhV)

Target
NhV
Molecular classification
Three-finger toxin, Phospholipase A2, Snake venom metalloproteinase, Cytotoxin
01

Overview

The venom toxins from Naja haje, commonly known as the Egyptian cobra, consist of a sophisticated mixture of proteins designed for prey immobilization and defense. The most significant components are the three-finger toxins (3FTx), particularly alpha-neurotoxins, which exhibit high affinity for nicotinic acetylcholine receptors at the neuromuscular junction, resulting in post-synaptic blockade and subsequent respiratory paralysis (UniProt, 2023). Beyond neurotoxicity, the venom contains cytotoxins that cause membrane disruption and localized tissue damage, as well as phospholipase A2 enzymes that mediate inflammatory responses and enzymatic degradation of phospholipids (PubMed, 2022). In medical practice, these toxins are the direct targets of antivenom therapy, where equine or ovine-derived antibodies are used to neutralize the venom's lethal effects (WHO, 2024). While the venom itself is a lethal cocktail, individual components are researched for potential therapeutic applications in pain management and anticoagulation due to their high specificity for ion channels and receptors (NIH, 2021).

Other names
Naja haje venomEgyptian cobra toxinsAsp venom
02

Mechanism of action

Antivenom antibodies bind to and sequester venom toxins, preventing their interaction with physiological targets such as nicotinic acetylcholine receptors and cell membranes (WHO, 2024).

03

Biological functions

Neuromuscular blockadeCell lysisProteolysisHemolysis
04

Disease associations

Snakebite envenomationRespiratory paralysisTissue necrosis
05

Safety considerations

AnaphylaxisSerum sicknessRapid respiratory failureAntivenom scarcity
06

Interacting drugs

Polyvalent snake antivenom

2 more in the full profile.

07

Biomarkers

Venom antigen levelsCreatine kinaseProthrombin time

Beyond the preview

Go deeper on Egyptian cobra venom toxins (NhV) (NhV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Egyptian cobra venom toxins (NhV) (NhV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call